MedDataX Logo

Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.

NCT ID: NCT03928145

Last Updated: 2019-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-13

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Thiazide diuretics have demonstrated favorable blood pressure lowering efficacy, safety profile and low cost, but it is still unclear what are the equivalence of doses of their more common agents, chlorthalidone and hydrochlorothiazide. Besides, concernments about adverse metabolic effects such as hypokalemia, hyperglycemia and hyperlipidemia do exist, which may be attenuated with the concomitant administration of a potassium-sparing diuretic, such as amiloride. In addition to control adverse effects of thiazides, amiloride could offer an additional blood pressure lowering effect, but the efficacy of different doses was not fully established. This study aims to investigate the blood pressure lowering efficacy of chlorthalidone and hydrochlorothiazide, in combination with amiloride in different doses, for the initial management in patients with primary hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a factorial (2x2) randomized double-blinded clinical trial comparing the association of a thiazide diuretic (chlorthalidone 25 mg/day or hydrochlorothiazide 50 mg/day) with a potassium-sparing diuretic (amiloride 10 mg/day or amiloride 20 mg/day) as first drug option in patients aged 30 to 75 years with primary hypertension. The thiazide diuretic and amiloride will be combined in a single capsule. The capsules will be of the same size and color, so that neither the researcher nor the patients can distinguish the treatment by their appearance. The primary outcome will be the mean change from baseline in 24-h systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM). The secondary outcomes will be the mean change from baseline in daytime and nighttime systolic and diastolic blood pressure measured by ABPM, mean change from baseline in systolic and diastolic blood pressure measured by office blood pressure, incidence of adverse events, variation of laboratory parameters and proportion of patients who achieved blood pressure control (\<140/90 mmHg and \<130/80 mmHg for office blood pressure and 24-h ABPM, respectively). The follow-up will last 12 weeks. For a P alpha of 0.05, power of 80%, and standard deviation of 9 mmHg, and absolute difference of 6 mmHg on systolic blood pressure on 24-h ABPM, it will be necessary to study a total of 76 patients. The sample size will be increased by 10% to compensate losses, resulting in 84 patients being randomized in total (42 for each arm).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hypertension Treatment Chlorthalidone Hydrochlorothiazide Amiloride

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

The trial has a factorial design, where participants will receive two simultaneous interventions: a thiazide diuretic (chlorthalidone 25 mg or hydrochlorothiazide 50 mg) and a potassium-sparing diuretic (amiloride 10 mg or amiloride 20 mg). Randomization will be done in 1:1:1:1 ratio, and participants will be randomly assigned to four groups: a) chlorthalidone 25 mg + amiloride 10 mg; b) chlorthalidone 25 mg + amiloride 20 mg; c) hydrochlorothiazide 50 mg + amiloride 10 mg; and d) hydrochlorothiazide 50 mg + amiloride 20 mg.
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
The study medication will have the same color, taste, consistency, odor and appearance. In this way, patients, care providers, outcome assessors and the entire research team will be blinded regarding the allocation to the treatment groups throughout the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chlorthalidone 25 mg + amiloride 20 mg

Chlorthalidone 25 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.

Group Type EXPERIMENTAL

Chlorthalidone 25 mg

Intervention Type DRUG

Chlorthalidone 25 mg taken orally in the morning for 12 weeks.

Amiloride 20 mg

Intervention Type DRUG

Amiloride 20 mg taken orally in the morning for 12 weeks.

Chlorthalidone 25 mg + amiloride 10 mg

Chlorthalidone 25 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.

Group Type ACTIVE_COMPARATOR

Chlorthalidone 25 mg

Intervention Type DRUG

Chlorthalidone 25 mg taken orally in the morning for 12 weeks.

Amiloride 10 mg

Intervention Type DRUG

Amiloride 10 mg taken orally in the morning for 12 weeks.

Hydrochlorothiazide 50 mg + amiloride 20 mg

Hydrochlorothiazide 50 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.

Group Type ACTIVE_COMPARATOR

Hydrochlorothiazide 50 mg

Intervention Type DRUG

Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.

Amiloride 20 mg

Intervention Type DRUG

Amiloride 20 mg taken orally in the morning for 12 weeks.

Hydrochlorothiazide 50 mg + amiloride 10 mg

Hydrochlorothiazide 50 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.

Group Type ACTIVE_COMPARATOR

Hydrochlorothiazide 50 mg

Intervention Type DRUG

Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.

Amiloride 10 mg

Intervention Type DRUG

Amiloride 10 mg taken orally in the morning for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chlorthalidone 25 mg

Chlorthalidone 25 mg taken orally in the morning for 12 weeks.

Intervention Type DRUG

Hydrochlorothiazide 50 mg

Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.

Intervention Type DRUG

Amiloride 20 mg

Amiloride 20 mg taken orally in the morning for 12 weeks.

Intervention Type DRUG

Amiloride 10 mg

Amiloride 10 mg taken orally in the morning for 12 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chlorthalidone Hydrochlorothiazide Amiloride Amiloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (age 30 to 75 years).
* Diagnosis of primary hypertension based on ABPM (mean 24-h systolic BP ≥130 mmHg or mean 24-h diastolic BP ≥80 mmHg).
* No current use of antihypertensive medication.

Exclusion Criteria

* Low life expectancy.
* Other indications for the use of diuretics.
* Intolerance or contraindications to the study drugs.
* Cardiovascular disease (heart failure, myocardial infarction or stroke).
* Secondary hypertension.
* Chronic kidney disease and / or abnormal renal function (creatinine \>1.5 mg/dL).
* Hyperkalemia (serum potassium \>5.5 mEq/L).
* Gout.
* Previous antihypertensive treatment with more than one drug.
* Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg measured through office blood pressure.
* Pregnancy or prospective pregnancy during the study.
* Lactating women.
Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto de Cardiologia do Rio Grande do Sul

OTHER

Sponsor Role collaborator

Hospital de Clinicas de Porto Alegre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Flavio Fuchs, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital de Clinicas de Porto Alegre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Flavio Fuchs, MD, PhD

Role: CONTACT

Phone: +55 51 3359.8344

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Flavio Fuchs, MD, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Martins VM, Helal L, Ferrari F, Bottino LG, Fuchs SC, Fuchs FD. Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial. Trials. 2019 Dec 16;20(1):736. doi: 10.1186/s13063-019-3909-z.

Reference Type DERIVED
PMID: 31843024 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-0553

Identifier Type: -

Identifier Source: org_study_id